![](https://porib.com/wp-content/uploads/2022/03/Cancers.jpg)
García-Sancho AM, Presa M, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
Cancers 2024, 16, 2301
![](https://porib.com/wp-content/uploads/2024/01/Journal-of-Health-Economics-and-Outcomes-Research.jpg)
Peral C, De Lossada A, Lwoff N, Espinoza-Cámac N, Casado MA, Burke T, Alvir J, Thakkar S, Ferri-Grazzi E
Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence insights from the CHESS II Study
JHEOR. 2024;11(1):122-133
![](https://porib.com/wp-content/uploads/2023/12/Transplantation-Reviews.jpg)
Aguado JM, Navarro D, Montoto C, Yébenes M, de Castro-Orós I
Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review
Transplantation Reviews. doi: 10.1016/j.trre.2023.100804
MÁS INFORMACIÓN
Martín A, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Eficiencia de axicabtagén ciloleucel en el tratamiento en segunda línea del linfoma B difuso de células grandes en España
LXV Congreso Nacional de la SEHH, XXXIX Congreso Nacional de la SETH y III Congreso Iberoamericano de Hematología. Sevilla. 26-28 oct 2023
Ortiz-Maldonado V, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Martín A
Axicabtagene Ciloleucel As Second-Line Treatment For Relapsed/ Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Peral C, de Lossada Juste A, Lwoff N, Espinoza Cámac N, Martínez-Martínez N, Casado MÁ, Burke T, Kane A, Alvir J, Thakkar S, Ferri Grazzi E
Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
![](https://porib.com/wp-content/uploads/2023/03/Sangre.jpg)
Álvarez-Román MT, Berrueco R, Haya S, Moretó A, R. López M, Mareque M, Casado MA, ConsensuHemos working group
Delphi consensus on managing prophylactic treatment in patients with severe hemophilia A in Spain
Sangre. 2023;42(1)
MÁS INFORMACIÓN
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C
Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C